Literature DB >> 3361452

2-(alpha-Naphthoyl)ethyltrimethylammonium iodide and its beta-isomer: new selective, stable and fluorescent inhibitors of choline acetyltransferase.

B V Sastry1, N Jaiswal, L K Owens, V E Janson, R D Moore.   

Abstract

The activities of 2-(alpha-naphthoyl)ethyltrimethylammonium (alpha-NETA) and its beta-isomer (beta-NETA) were studied at various sites of the cholinergic system using isolated enzyme and organ systems. They were selective inhibitors (I50: alpha-NETA, 9 microM; beta-NETA, 76 microM) of choline acetyltransferase (ChA). The inhibition of ChA by both alpha- and beta-NETA was noncompetitive with acetylcoenzyme A or choline as the variable substrate. In these experiments, the inhibitor and both substrates were added simultaneously to the reaction medium, and short reaction times of 10 min were used to determine initial linear velocities. Under these experimental conditions in the presence of substrates, the degree of inhibition of ChA by alpha-NETA was independent of enzyme concentration indicating the reversibility of the inhibition. If ChA was incubated with alpha-NETA for 10 min in the absence of substrates, the degree of inhibition was higher and was not reversible by dialysis of the inhibited ChA. These observations indicate that alpha-NETA is a pseudo-reversible or slowly reversible inhibitor. Neither alpha- nor beta-NETA exhibited significant effects at muscarinic receptors, ganglionic nicotinic receptors, skeletal muscular nicotinic receptors, cholinesterases or carnitine acetyltransferase at concentrations which inhibited ChA. At concentrations higher than their I50 values to inhibit ChA, both antagonized the effects of acetylcholine (ED50: alpha-NETA, 70-80 microM; beta-NETA, 100 microM), histamine and KCl-induced contractions in the guinea pig longitudinal ileal muscle. At high concentrations, alpha-NETA activated acetylcholinesterase (EC50, 360 microM) and inhibited cholinesterase (EC50, 1100 microM).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361452

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Soluble miniagrin enhances contractile function of engineered skeletal muscle.

Authors:  Weining Bian; Nenad Bursac
Journal:  FASEB J       Date:  2011-11-10       Impact factor: 5.191

2.  Discovery of novel cyclophilin A ligands using an H/D exchange- and mass spectrometry-based strategy.

Authors:  Patrick D Dearmond; Graham M West; Victor Anbalagan; Michael J Campa; Edward F Patz; Michael C Fitzgerald
Journal:  J Biomol Screen       Date:  2010-09-20

3.  Parental Dietary Protein Source and the Role of CMKLR1 in Determining the Severity of Dahl Salt-Sensitive Hypertension.

Authors:  Justine M Abais-Battad; Hayley Lund; Daniel J Fehrenbach; John Henry Dasinger; Ammar J Alsheikh; David L Mattson
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

4.  Identification of TAAR5 Agonist Activity of Alpha-NETA and Its Effect on Mismatch Negativity Amplitude in Awake Rats.

Authors:  Aleksander A Aleksandrov; Veronika M Knyazeva; Anna B Volnova; Elena S Dmitrieva; Olga Korenkova; Stefano Espinoza; Andrey Gerasimov; Raul R Gainetdinov
Journal:  Neurotox Res       Date:  2018-05-01       Impact factor: 3.911

5.  A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease.

Authors:  Kareem L Graham; Jian V Zhang; Susanna Lewén; Thomas M Burke; Ton Dang; Maria Zoudilova; Raymond A Sobel; Eugene C Butcher; Brian A Zabel
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

6.  Discovery of novel choline acetyltransferase inhibitors using structure-based virtual screening.

Authors:  Rajnish Kumar; Amit Kumar; Bengt Långström; Taher Darreh-Shori
Journal:  Sci Rep       Date:  2017-11-24       Impact factor: 4.379

Review 7.  Acetylcholine signaling system in progression of lung cancers.

Authors:  Jamie R Friedman; Stephen D Richbart; Justin C Merritt; Kathleen C Brown; Nicholas A Nolan; Austin T Akers; Jamie K Lau; Zachary R Robateau; Sarah L Miles; Piyali Dasgupta
Journal:  Pharmacol Ther       Date:  2018-10-03       Impact factor: 13.400

8.  Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization.

Authors:  Rajnish Kumar; Bengt Långström; Taher Darreh-Shori
Journal:  Sci Rep       Date:  2016-08-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.